相关实验视频
Updated: Jun 30, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
帕金森病中的皮下利沃多巴:系统性审查和元分析
Matthew Burton1, Duncan Marsden1, Dhruv Harish1
1University of Oxford Medical Sciences Division, Oxford, UK.
European journal of neurology
|January 29, 2026
概括
在帕金森病患者中,持续的皮下勒沃多巴/卡比多巴输液显著减少了OFF时间. 这种新疗法改善了生活质量,尽管输液部位事件更为常见.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 帕金森病 (PD) 患者经常经历口服乐伏多巴/卡比多巴的"减效".
- 较高的口服剂量会增加多巴胺水平的峰值,导致运动障碍.
- 持续的皮下输液提供了一种新的策略,可以减少OFF时间,而不会产生高峰剂量的不良影响.
研究的目的:
- 为了评估皮下勒沃多巴/卡比多巴输液疗法的安全性和有效性.
- 将OFF时间减少和生活质量得分与口服levodopa/carbidopa进行比较.
主要方法:
- 在MEDLINE,Embase,CENTRAL和ICTRP的系统文献搜索到2024年10月.
- 包括临床试验,比较皮下输注levodopa/foslevodopa与帕金森病患者口服的levodopa.
- 分析了7项涉及725名患者的研究的数据.
主要成果:
- 皮下输液减少了每日OFF时间1.98小时 (p=0.0004).
- 观察到与健康相关的生活质量 (PDQ-39,p=0.0003) 和睡眠 (PDSS-2,p=0.02) 的改善.
- 治疗出现的不良事件增加,主要是输液部位反应 (p=0.04).
结论:
- 皮下输液疗法在帕金森病中显著减少了OFF时间.
- 虽然生活质量在统计上有所改善,但临床意义尚未确定.
- 这种方法为PD患者带有运动波动提供了潜在的替代方案,尽管输液部位发生了不良事件.
相关概念视频
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...